Workflow
Test
icon
Search documents
Here's Why Teradyne (TER) Fell More Than Broader Market
ZACKS· 2025-07-11 23:16
Company Performance - Teradyne's stock closed at $97.05, reflecting a -1.59% change from the previous day's closing price, underperforming compared to the S&P 500's -0.33% loss [1] - Over the past month, Teradyne's stock has increased by 14.8%, outperforming the Computer and Technology sector's gain of 5.24% and the S&P 500's gain of 4.07% [1] Upcoming Earnings - Teradyne is expected to report an EPS of $0.54, which represents a 37.21% decrease from the same quarter last year [2] - The consensus estimate for revenue is $646.05 million, indicating an 11.49% decrease compared to the same quarter of the previous year [2] Full Year Projections - For the full year, earnings are projected at $3.17 per share, reflecting a -1.55% change from the prior year, while revenue is expected to be $2.91 billion, representing a +3.18% change [3] Analyst Estimates - Recent changes to analyst estimates for Teradyne are important as they indicate shifts in near-term business trends, with upward revisions suggesting positive sentiment towards the company's operations [4] - The Zacks Consensus EPS estimate has increased by 0.21% over the past month, and Teradyne currently holds a Zacks Rank of 3 (Hold) [6] Valuation Metrics - Teradyne's Forward P/E ratio is 31.11, indicating a premium compared to its industry's Forward P/E of 19.35 [6] - The company has a PEG ratio of 4.3, while the average PEG ratio for the Electronics - Miscellaneous Products industry is 1.8 [7] Industry Context - The Electronics - Miscellaneous Products industry, part of the Computer and Technology sector, has a Zacks Industry Rank of 87, placing it in the top 36% of over 250 industries [7][8] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [8]
FormFactor to Announce Second Quarter 2025 Financial Results on July 30th
Globenewswire· 2025-07-09 20:01
LIVERMORE, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq: FORM) will report financial results for its 2025 fiscal second quarter on Wednesday, July 30th, 2025, at 1:25 p.m. Pacific Time. The public is invited to listen to a live webcast of FormFactor's conference call on the Investors section of the company's web site at www.formfactor.com. To Listen via Telephone: Preregistration is required. Please preregister by clicking here. Upon registering, you will be emailed a dial-in number, ...
X @The Economist
The Economist· 2025-07-09 14:00
Joe Rogan touts testosterone shots to his 20m listeners as a way to help men feel younger. Gym-bros and “biohackers” inject themselves with it on TikTok. Are they promoting something safe? https://t.co/byLysWpsLK ...
Leslie's(LESL) - 2022 FY - Earnings Call Presentation
2025-07-09 12:12
Company Overview - Leslie's is the largest direct-to-consumer brand in the pool and spa care industry, with fiscal year 2021 sales exceeding $1.3 billion, representing a 20.7% sales growth[14] - The company's adjusted EBITDA for fiscal year 2021 was $271 million, a 48% increase[14] - Leslie's operates 970 locations across 39 states[24] Market Opportunity - The U S pool and spa aftermarket opportunity is estimated at $14 billion[22, 35] - The addressable market includes 8.7 million residential pools representing a $7.6 billion total addressable market (TAM)[31] - There are 5.5 million addressable spas representing a $2 billion TAM[33] - The professional pool market includes 250,000 commercial pools and 45,000 pool professionals, representing a $4.3 billion TAM[35] Growth & Financial Performance - First half of fiscal year 2022 sales reached $413 million, a 22% increase[82] - The company's first half of fiscal year 2022 adjusted EBITDA grew by 5.5% to $10 million[82] - The PRO business grew by 27% in the first half of fiscal year 2022 and represents approximately 15% of last twelve months (LTM) total sales[85] Fiscal Year 2022 Guidance - Revised fiscal year 2022 sales guidance is between $1.575 billion and $1.61 billion, representing a 17%-20% growth[89] - Revised fiscal year 2022 adjusted EBITDA is projected to be between $315 million and $330 million, a 16%-22% increase[89]
近亿元融资!数问生物完成C1轮
思宇MedTech· 2025-07-09 10:36
近日, 浙江数问生物技术有限公司 (以下简称"数问生物")宣布完成 近亿元C1轮融资 ,并 同步启动C2轮 融资 。本轮融资由金创投领投,老股东元生创投继续跟投。融资资金将主要用于 公司全球首创诊断产品的国 内外市场推广及新产品研发投入 ,进一步完善女性健康精准诊疗产品管线。 # 关于数问生物 数问生物 成立于2011年,总部位于浙江德清莫干山国家高新区,是一家专注于女性健康体外诊断试剂开发、 生产、销售和医学检验服务的国际化企业。公司在杭州、金华、安徽宣城及德国柏林设有研发、生产和销售基 地,是国家级高新技术企业,拥有" 创新医学诊断省级企业研发中心 "和 浙江省唯一 的" 创新标志物医学诊 断技术国际合作基地 "。 公司与耶鲁大学、芝加哥大学、德国马普研究所、德国科隆大学、复旦大学附属肿瘤医院、BioNTech、 Myriad Genetics等多家国际知名机构建立了长期合作关系,累计获得 100多项独家诊断专利 ,开发了 多个 全球首创的诊断产品 。 产品与技术介绍 数问生物的产品线聚焦于女性健康的两大核心领域: 母婴医学与乳腺癌精准诊疗 。 母婴健康 :公司推出了 全球首个 获批上市的孕妇子痫前期家用 ...
逆势完成C1轮融资并开启C2轮融资,数问生物加速全球化市场布局
近日,浙江数问生物技术有限公司("数问生物")宣布完成近亿元C1轮融资并开启C2轮融资。本轮融资由 金创投领投,老股东元生创投持续注资。融资资金将用于加速数问生物全球首创诊断产品的国内外市场 推广,同时加大新产品研发投入,进一步丰富和完善公司的女性健康精准诊疗产品管线。 数问生物是一家专注于女性健康体外诊断试剂开发、生产、销售和医学检验服务的国际化公司。先后与 美国耶鲁大学、芝加哥大学、德国马普研究所、德国科隆大学、复旦大学附属肿瘤医院、BioNTech、 MyriadGenetics等众多国内外知名院校、企业和研究机构签订独家合作协议,并结合自主创新,获得了 100多项独家诊断专利,成功开发了多个同类首创的诊断新产品和服务,在女性健康,包括母婴医学和 乳腺癌精准医疗领域形成了系列化独特产品和服务。 数问生物是一家专注于创新体外诊断试剂及配套仪器开发、生产、销售和医学检验服务的国际化企业, 打造女性健康诊断领域的国际化的龙头企业。总部位于浙江德清莫干山国家高新区,在杭州、金华、安 徽宣城、德国柏林设有研发、生产和销售基地和团队,是国家级高新技术企业,拥有"创新医学诊断省 级企业研发中心"和完善的诊断试剂盒生产 ...
X @The Economist
The Economist· 2025-07-08 20:01
Between 2019 and 2024 prescriptions for testosterone in America jumped from 7.3m to 11m. What explains this health fad? https://t.co/R7qyOscWuS ...
INOD Stock Expands GenAI Offerings: Can it Drive Enterprise Growth?
ZACKS· 2025-07-08 16:31
Key Takeaways INOD secured $8M in new deals from four Big Tech clients in the reported quarter. New GenAI tools, including a test platform built on NVIDIA tech, are driving enterprise demand for INOD. DDS now contributes over 87% of total revenue, highlighting its central role in INOD's business.Innodata (INOD) is benefiting from the increasing demand for generative AI, fueling growth in its Digital Data Solutions (DDS) segment. DDS revenues reached $50.8 million in the first quarter of 2025, accounting f ...
Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes
Prnewswire· 2025-07-08 12:00
HENDERSON, Nev., July 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it has demonstrated quantification of nucleosomes in whole venous blood in minutes utilizing a simple lateral flow device. The blinded study, part of the SUMMIT program,  tested blood samples from 25 hospital patients in Intensive Care or at the Emergency Department. The results correlated strongly with those of Volition's established automated central la ...
X @The Wall Street Journal
As more companies are selling nutrition and health-testing services, a WSJ reporter decided to try one. Things got weird. https://t.co/aU4EPFGpP8 ...